Clinical Trial Update: Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement [Phase 1]

View source ↗

Summary

Phase 1 study evaluating AGG-523 in subjects with severe osteoarthritis requiring total knee replacement has completed; Wyeth (now Pfizer) sponsored the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• AGG-523

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Osteoarthritis | Phase 1 | Status: COMPLETED